Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06422143
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-05-15
Brief Title:
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan Sac-TMT MK-2870 in Metastatic Squamous Non-small Cell Lung Cancer NSCLC MK-2870-023
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-10
Start Date Type:
ACTUAL
Primary Completion Date:
2029-01-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-02-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-15
First Submit QC Date:
May 15 2024
Study First Post Date:
2024-05-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-07-15
Last Update Post Date Type:
ESTIMATED